ResMed Elects Jan De Witte to Its Board of Directors
May 16 2019 - 4:05PM
Business Wire
- De Witte’s 30+ years of global
healthcare and technology experience will bolster ResMed’s board
capabilities
- Current CEO based in Europe brings
valuable perspective to help guide ResMed’s expanding global
connected health businesses
- Long-serving director Jack Wareham to
retire in November 2019
ResMed (NYSE: RMD, ASX: RMD), a leader in cloud-connected
medical devices and out-of-hospital SaaS solutions, today announced
it has elected experienced business executive Jan De Witte to its
board of directors.
Mr. De Witte was appointed during ResMed’s regularly scheduled
board meeting on May 16, 2019, to fill a newly created
directorship, effective immediately. Also at that meeting, Jack
Wareham announced he intends to retire from ResMed’s board after
serving since January 2005. Mr. Wareham’s resignation will be
effective at ResMed’s November 2019 annual stockholders
meeting.
De Witte has more than 30 years’ experience in health and
technology products as an executive and business leader in the
United States and Europe. He is currently CEO and board member of
Barco NV., positions he has held since 2016. Barco, a global
technology company, designs and develops visualization and
collaboration technology solutions for the healthcare, enterprise,
and entertainment markets.
Before joining Barco as CEO, De Witte was president and CEO of
General Electric’s Global Healthcare IT business, a $1.6 billion
revenue business with more than 4,500 employees worldwide that
provides software solutions to healthcare providers. This position
capped a 17-year career with General Electric’s healthcare
business, based in the United States and France.
Before General Electric, De Witte worked at McKinsey &
Company Inc. from 1993 to 1998 in Brussels, Amsterdam, and Zurich,
serving clients in the industrial and transportation sector on
strategy and business development, business process re-engineering
and operational improvement. From 1987 to 1991, he worked at the
Procter & Gamble Company in Belgium in various production
planning, logistics, and supply chain roles.
De Witte holds a Master’s degree in electromechanical
engineering from the Katholieke Universiteit Leuven in Belgium, and
an MBA from Harvard University in Cambridge, Mass.
“I’m pleased to welcome Jan De Witte to ResMed’s Board,”
said ResMed Founder and Board Chairman Peter Farrell. “His
perspective as CEO of a global technology company, coupled with his
three decades of healthcare and technology experience, will benefit
ResMed as it continues its global leadership in connected medical
devices and out-of-hospital software.”
“I'd also like to thank Jack Wareham for his insights and
circumspect guidance to ResMed over the past 14 years of service as
a director,” said Farrell. “Jack’s experience as CEO of Beckman
Coulter gave him the background to provide exceptionally wise
counsel to the board and management.”
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions
that treat and keep people out of the hospital, empowering them to
live healthier, higher-quality lives. Our cloud-connected medical
devices transform care for people with sleep apnea, COPD and other
chronic diseases. Our comprehensive out-of-hospital software
platforms support the professionals and caregivers who help people
stay healthy in the home or care setting of their choice. By
enabling better care, we improve quality of life, reduce the impact
of chronic disease and lower costs for consumers and healthcare
systems in more than 120 countries. To learn more, visit
ResMed.com and follow @ResMed.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190516006016/en/
For media:Jayme Rubenstein+1
858.836.6798news@resmed.com
For investors:Amy Wakeham+1
858.836.5000investorrelations@resmed.com
Resmed (ASX:RMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Resmed (ASX:RMD)
Historical Stock Chart
From Apr 2023 to Apr 2024